Works by Gelmon, K.

Results: 27

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.

Published in:

Investigational New Drugs, 2013, v. 31, n. 6, p. 1522, doi. 10.1007/s10637-013-0018-9

By:

Dent, S.;
Gelmon, K.;
Chi, K.;
Jonker, D.;
Wainman, N.;
Capier, C.;
Chen, E.;
Lyons, J.;
Seymour, L.

Publication type:

Article

TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.

Published in:

British Journal of Cancer, 2015, v. 113, n. 5, p. 722, doi. 10.1038/bjc.2015.271

By:

Bartlett, J M S;
Nielsen, T O;
Gao, D;
Gelmon, K A;
Quintayo, M A;
Starczynski, J;
Han, L;
Burnell, M J;
Levine, M N;
Chen, B E;
Shepherd, L E;
Chapman, J W

Publication type:

Article

Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy.

Published in:

British Journal of Cancer, 2014, v. 111, n. 9, p. 1718, doi. 10.1038/bjc.2014.466

By:

Courneya, K S;
McKenzie, D C;
Mackey, J R;
Gelmon, K;
Friedenreich, C M;
Yasui, Y;
Reid, R D;
Vallerand, J R;
Adams, S C;
Proulx, C;
Dolan, L B;
Wooding, E;
Segal, R J

Publication type:

Article

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.

Published in:

British Journal of Cancer, 2012, v. 107, n. 5, p. 800, doi. 10.1038/bjc.2012.338

By:

Wishart, G C;
Bajdik, C D;
Dicks, E;
Provenzano, E;
Schmidt, M K;
Sherman, M;
Greenberg, D C;
Green, A R;
Gelmon, K A;
Kosma, V-M;
Olson, J E;
Beckmann, M W;
Winqvist, R;
Cross, S S;
Severi, G;
Huntsman, D;
Pylkäs, K;
Ellis, I;
Nielsen, T O;
Giles, G

Publication type:

Article

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.

Published in:

2010

By:

Dawson, S.-J.;
Makretsov, N.;
Blows, F. M.;
Driver, K. E.;
Provenzano, E.;
Le Quesne, J.;
Baglietto, L.;
Severi, G.;
Giles, G. G.;
McLean, C. A.;
Callagy, G.;
Green, A. R.;
Ellis, I.;
Gelmon, K.;
Turashvili, G.;
Leung, S.;
Aparicio, S.;
Huntsman, D.;
Caldas, C.;
Pharoah, P.

Publication type:

Correction Notice

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.

Published in:

2010

By:

Dawson, S-J;
Makretsov, N;
Blows, F M;
Driver, K E;
Provenzano, E;
Le Quesne, J;
Baglietto, L;
Severi, G;
Giles, G G;
McLean, C A;
Callagy, G;
Green, A R;
Ellis, I;
Gelmon, K;
Turashvili, G;
Leung, S;
Aparicio, S;
Huntsman, D;
Caldas, C;
Pharoah, P

Publication type:

journal article

Cessation of zidovudine therapy may lead to increased replication of HIV-1.

Published in:

1989

By:

Wainberg, Mark A.;
Falutz, Julian;
Fanning, Mary;
Gill, John;
Gelmon, Karen;
Montaner, Julio S.G.;
O'Shaughnessy, Michael;
Tsoukas, Chris;
Ruedy, John;
Wainberg, M A;
Falutz, J;
Fanning, M;
Gill, J;
Gelmon, K;
Montaner, J S;
O'Shaughnessy, M;
Tsoukas, C;
Ruedy, J

Publication type:

Letter

Neoadjuvant therapy for breast cancer: updates and proceedings from the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer.

Published in:

Current Oncology, 2018, v. 25, n. 5, p. e490, doi. 10.3747/co.25.4153

By:

Arnaout, A.;
Lee, J.;
Gelmon, K.;
Poirier, B.;
Lu, F. I.;
Akra, M.;
Boileau, J. F.;
Tonkin, K.;
Li, H.;
Illman, C.;
Simmons, C.;
Grenier, D.

Publication type:

Article

Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience.

Published in:

Current Oncology, 2015, v. 22, n. 3, p. 192, doi. 10.3747/co.22.2284

By:

Baxter, E.;
Gondara, L.;
Lohrisch, C.;
Chia, S.;
Gelmon, K.;
Hayes, M.;
Davidson, A.;
Tyldesley, S.

Publication type:

Article

Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience.

Published in:

Current Oncology, 2015, v. 22, n. 3, p. 192, doi. 10.3747/co.22.2284

By:

Baxter, E.;
Gondara, L.;
Lohrisch, C.;
Chia, S.;
Gelmon, K.;
Hayes, M.;
Davidson, A.;
Tyldesley, S.

Publication type:

Article

Endocrine therapy for postmenopausal women with hormone receptor-positive HER2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement.

Published in:

Current Oncology, 2013, v. 20, n. 1, p. 48, doi. 10.3747/co.20.1316

By:

Pritchard, Kathy I.;
Gelmon, K. A.;
Rayson, D.;
Provencher, L.;
Webster, M.;
McLeod, D.;
Verma, S.

Publication type:

Article

Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.

Published in:

Current Oncology, 2012, v. 19, n. 5, p. 259, doi. 10.3747/co.19.1011

By:

Clemons, M.;
Gelmon, K. A.;
Pritchard, K. I.;
Paterson, A. H. G.

Publication type:

Article

Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab.

Published in:

Current Oncology, 2012, v. 19, n. 4, p. 197, doi. 10.3747/co.19.960

By:

Seal, M. D.;
Speers, C. H.;
O'Reilly, S.;
Gelmon, K. A.;
Ellard, S. L.;
Chia, S. K.

Publication type:

Article

Is Canadian women's breast cancer screening behaviour associated with having a family doctor?

Published in:

2010

By:

Poole B;
Black C;
Gelmon K;
Kan L;
Poole, Barbara;
Black, Charlyn;
Gelmon, Karen;
Kan, Lisa

Publication type:

journal article

PI-13.

Published in:

Clinical Pharmacology & Therapeutics, 2006, v. 79, n. 2, p. P10, doi. 10.1016/j.clpt.2005.12.034

By:

Guo, F.;
Letrent, S. P.;
Noe, D. A.;
Qin, A.;
Rohrbacher, K. D.;
Munster, P. N.;
Tolcher, A. W.;
Britten, C. D.;
Gelmon, K.;
Sharma, A.

Publication type:

Article

Pharmacokinetics of Trastuzumab in Combination With Paclitaxel Given Every 3 Weeks in Women With HER2 Positive Metastatic Breast Cancer.

Published in:

Clinical Pharmacology & Therapeutics, 2003, v. 73, n. 2, p. P83, doi. 10.1016/S0009-9236(03)90662-X

By:

Ghahramani, P.;
Lennon, S. M.;
Leyland-Jones, B.;
Gelmon, K.

Publication type:

Article

Effect of news media coverage of cancer risk on clinical oncology practice.

Published in:

2001

By:

Lee, Christopher W.;
Weir, Lorna;
Gielmon, Karen A.;
Lee, C W;
Weir, L;
Gelmon, K A

Publication type:

commentary

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

Published in:

1999

By:

Gelmon, Karen A.;
Eisenhauer, Elizabeth A.;
Gelmon, K A;
Eisenhauer, E A;
Harris, A L;
Ratain, M J;
Workman, P

Publication type:

journal article

Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.

Published in:

Cancer & Metastasis Reviews, 2016, v. 35, n. 3, p. 427, doi. 10.1007/s10555-016-9631-3

By:

Yeung, C.;
Hilton, J.;
Clemons, M.;
Mazzarello, S.;
Hutton, B.;
Haggar, F.;
Addison, C.;
Kuchuk, I.;
Zhu, X.;
Gelmon, K.;
Arnaout, A.

Publication type:

Article

Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.

Published in:

Oncogene, 2010, v. 29, n. 48, p. 6343, doi. 10.1038/onc.2010.366

By:

Kalra, J;
Sutherland, B W;
Stratford, A L;
Dragowska, W;
Gelmon, K A;
Dedhar, S;
Dunn, S E;
Bally, M B

Publication type:

Article

Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer.

Published in:

British Journal of Cancer, 1999, v. 80, n. 12, p. 1979, doi. 10.1038/sj.bjc.6690630

By:

Bebb, D G;
Yu, Z;
Chen, J;
Telatar, M;
Gelmon, K;
Phillips, N;
Gatti, R A;
Glickman, B W

Publication type:

Article

Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.

Published in:

2008

By:

Giltnane JM;
Molinaro A;
Cheng H;
Robinson A;
Turbin D;
Gelmon K;
Huntsman D;
Rimm DL

Publication type:

Journal Article

HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab [corrected] [published erratum appears in ARCH PATHOL LAB MED 2008 May;132(5):730].

Published in:

2008

By:

O'Malley FP;
Thomson T;
Julian J;
Have C;
Crosby R;
Gelmon K;
Andrulis I;
Whelan T

Publication type:

Journal Article

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.

Published in:

Investigational New Drugs, 2020, v. 38, n. 5, p. 1442, doi. 10.1007/s10637-020-00904-7

By:

Nehra, J.;
Bradbury, P. A.;
Ellis, P. M.;
Laskin, J.;
Kollmannsberger, C.;
Hao, D.;
Juergens, R. A.;
Goss, G.;
Wheatley-Price, P.;
Hotte, S. J.;
Gelmon, K.;
Tinker, A. V.;
Brown-Walker, P.;
Gauthier, I.;
Tu, D.;
Song, X.;
Khan, A.;
Seymour, Lesley;
Smoragiewicz, M.

Publication type:

Article

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.

Published in:

Breast Cancer Research & Treatment, 2019, v. 174, n. 3, p. 719, doi. 10.1007/s10549-018-05125-4

By:

Rugo, H. S.;
Finn, R. S.;
Diéras, V.;
Ettl, J.;
Lipatov, O.;
Joy, A. A.;
Harbeck, N.;
Castrellon, A.;
Iyer, S.;
Lu, D. R.;
Mori, A.;
Gauthier, E. R.;
Bartlett, C. Huang;
Gelmon, K. A.;
Slamon, D. J.

Publication type:

Article

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Published in:

Breast Cancer Research & Treatment, 2018, v. 167, n. 2, p. 485, doi. 10.1007/s10549-017-4538-4

By:

Bernstein, V.;
Ellard, S. L.;
Dent, S. F.;
Tu, D.;
Mates, M.;
Dhesy-Thind, S. K.;
Panasci, L.;
Gelmon, K. A.;
Salim, M.;
Song, X.;
Clemons, M.;
Ksienski, D.;
Verma, S.;
Simmons, C.;
Lui, H.;
Chi, K.;
Feilotter, H.;
Hagerman, L. J.;
Seymour, L.

Publication type:

Article

Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials

Published in:

Breast Cancer Research & Treatment, 2013, v. 142, n. 1, p. 143, doi. 10.1007/s10549-013-2714-8

By:

Hilton, J.;
Bouganim, N.;
Dong, B.;
Chapman, J.;
Arnaout, A.;
O'Malley, F.;
Gelmon, K.;
Yerushalmi, R.;
Levine, M.;
Bramwell, V.;
Whelan, T.;
Pritchard, K.;
Shepherd, L.;
Clemons, M.

Publication type:

Article